Personalis Inc

PSNL

Add to Watchlist

6.360USD

-0.350-5.22%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Personalis Inc's Score

Industry at a Glance

Industry Ranking

75 / 382

Overall Ranking

189 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Personalis Inc Highlights

StrengthsRisks

Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.

Growing

The company is in a growing phase, with the latest annual income totaling USD 69.65M.

Undervalued

The company’s latest PE is -6.24, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 65.32M shares, increasing 2.84% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 36.58K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.70.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

10.857

Target Price

+61.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Personalis Inc is 6.48, ranking 235 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 15.47M, representing a year-over-year decrease of 24.91%, while its net profit experienced a year-over-year decrease of 90.68%.

Score

Industry at a Glance

Previous score

6.48

Change

0



Financials

8.34

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.91

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.36

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Personalis Inc is 6.10, ranking 319 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.24, which is -93.75% below the recent high of -0.39 and -115.17% above the recent low of -13.43.

Score

Industry at a Glance

Previous score

6.10

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Personalis Inc is 8.29, ranking 137 out of 382 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 12.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.29

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Personalis Inc is 9.08, ranking 33 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.52 and the support level at 5.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.33

Change

-0.25

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Personalis Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 62.66%, representing a quarter-over-quarter decrease of 7.44%. The largest institutional shareholder is Catherine Wood, holding a total of 7.94M shares, representing 7.59% of shares outstanding, with 6.79% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Merck & Co Inc

14.04M

--

Tempus AI Inc

13.04M

+0.93%

Lightspeed Venture Partners

8.16M

--

ARK Investment Management LLC

Star Investors

7.88M

-0.39%

T. Rowe Price Investment Management, Inc.

10.78M

+273.85%

BlackRock Institutional Trust Company, N.A.

4.32M

-0.22%

Columbia Threadneedle Investments (UK)

3.51M

--

abrdn Inc.

3.25M

+36.10%

Columbia Threadneedle Investments (US)

2.62M

+774.98%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Personalis Inc is 3.14, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.96. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Personalis Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Personalis Inc

PSNL

6.82 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment